Viewing data from:

HYDROMORPHONE HYDROCHLORIDE

NDA

HYDROMORPHONE HYDROCHLORIDE | N217812 | HIKMA PHARMACEUTICALS USA INC

1 strength1 unique patent0 unique exclusivities

Patent Timeline

1 unique patent by expiration date

Active (1)Today

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

2040

2041

2042

2043

Today

12653820

Jan. 10, 2043

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

153 trials from ClinicalTrials.gov — 2 recruiting, 3 active, 111 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain NCT04296305	Phase 4	Active	M.D. Anderson Cancer Center	84	2020-09-10 → 2027-12-31
Multimodal Analgesia Effect on Post Surgical Patient NCT04240626	Phase 4	Active	University of California, Davis	60	2021-01-20 → 2026-06-24
Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery NCT03214510	Phase 3	Active	M.D. Anderson Cancer Center	101	2017-10-04 → 2026-07-31
Spinal Anesthesia For Enhanced Recovery After Liver Surgery NCT03715517	N/A	Recruiting	University of Manitoba	128	2018-10-04 → 2031-12-31
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery NCT03893734	Phase 4	Recruiting	Endeavor Health	140	2018-05-01 → 2020-12-23
Association Between Body Size and Response to Hydromorphone in ED NCT01675778	Phase 2	Completed	Albert Einstein College of Medicine	174	2011-10 → 2012-12
Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery NCT02423876	Phase 3	Completed	University of Wisconsin, Madison	104	2015-03-17 → 2022-01-03
Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.NCT02437669	Phase 2	Completed	Columbia University	35	2015-05 → 2018-04
Comparison of Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia (PCA)NCT00385541	Phase 4	Completed	Columbia University	50	2003-11 → 2007-10
The Discriminative Effects of Tramadol in Humans NCT00499746	Phase 1/2	Completed	National Institute on Drug Abuse (NIDA)	20	2007-11 → 2011-08

Source: ClinicalTrials.gov. Trials matched by ingredient name.

VA Federal Supply Schedule

Government-negotiated contract prices | 1 NDC (1 FSS)

Lowest Price

$15.96

Highest Price

$15.96

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00641-6254-01HYDROMORPHONE HCL 2MG/ML INJ	$15.96	FSS	Hikma Pharmaceuticals USA Inc.	08/14/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain4 active DMFs6 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

NORAMCO LLCHYDROMORPHONE HYDROCHLORIDE DRUG SUBSTANCE

DMF 195612006

SIEGFRIED USA LLCHYDROMORPHONE HYDROCHLORIDE USP

DMF 220822008

SPECGX LLCHYDROMORPHONE HYDROCHLORIDE USP (NP)

DMF 257662012

CHATTEM CHEMICALS INCHYDROMORPHONE HYDROCHLORIDE, USP

DMF 309952016

DIOSYNTH BVInactiveHYDROMORPHONE HYDROCHLORIDE

DMF 70111987

TAKEDA PHARMACEUTICAL CO LTDInactiveHYDROMORPHONE HYDROCHLORIDE

DMF 70711987

SPECGX LLCInactiveHYDROMORPHONE HYDROCHLORIDE

DMF 72371987

NORAMCO LLCInactiveHYDROMORPHONE HYDROCHLORIDE USP

DMF 163512002

CODY LABORATORIES INCInactiveHYDROMORPHONE HYDROCHLORIDE USP

DMF 288042014

NORAMCO LLCInactiveHYDROMORPHONE HYDROCHLORIDE USP

DMF 319942020

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Dec 29, 2025	SUPPL -1	View Letter (PDF)
Dec 15, 2023	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 40MG/20ML (2MG/ML)

RLD

1 patent0 exclusivities▴

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | Approved: Dec 14, 2023

Patents (1) · 1 use code

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
12653820Newly listed — daily FDA feed, not yet in monthly Orange Book edition	Jan 10, 2043	—	—	Yes		—